Limits...
The role of citicoline in neuroprotection and neurorepair in ischemic stroke.

Alvarez-Sabín J, Román GC - Brain Sci (2013)

Bottom Line: Advances in acute stroke therapy resulting from thrombolytic treatment, endovascular procedures, and stroke units have improved significantly stroke survival and prognosis; however, for the large majority of patients lacking access to advanced therapies stroke mortality and residual morbidity remain high and many patients become incapacitated by motor and cognitive deficits, with loss of independence in activities of daily living.Citicoline has therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke and has demonstrated efficiency in a multiplicity of animal models of acute stroke.Long-term treatment with citicoline is safe and effective, improving post-stroke cognitive decline and enhancing patients' functional recovery.

View Article: PubMed Central - PubMed

Affiliation: Neurovascular Unit, Department of Neurology, Universitat Autónoma de Barcelona, 119-129 Passeig de la Vall d'Hebron, Barcelona 08035, Spain. josalvarez@vhebron.net.

ABSTRACT
Advances in acute stroke therapy resulting from thrombolytic treatment, endovascular procedures, and stroke units have improved significantly stroke survival and prognosis; however, for the large majority of patients lacking access to advanced therapies stroke mortality and residual morbidity remain high and many patients become incapacitated by motor and cognitive deficits, with loss of independence in activities of daily living. Therefore, over the past several years, research has been directed to limit the brain lesions produced by acute ischemia (neuroprotection) and to increase the recovery, plasticity and neuroregenerative processes that complement rehabilitation and enhance the possibility of recovery and return to normal functions (neurorepair). Citicoline has therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke and has demonstrated efficiency in a multiplicity of animal models of acute stroke. Long-term treatment with citicoline is safe and effective, improving post-stroke cognitive decline and enhancing patients' functional recovery. Prolonged citicoline administration at optimal doses has been demonstrated to be remarkably well tolerated and to enhance endogenous mechanisms of neurogenesis and neurorepair contributing to physical therapy and rehabilitation.

No MeSH data available.


Related in: MedlinePlus

Probability of total recovery according to daily dose of citicoline among patients included in the pooled data analysis (N = 789 subjects on citicoline compared with 583 on placebo).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061873&req=5

brainsci-03-01395-f002: Probability of total recovery according to daily dose of citicoline among patients included in the pooled data analysis (N = 789 subjects on citicoline compared with 583 on placebo).

Mentions: Following a comprehensive review, a total of 1372 patients were included in the data pooling analysis, 789 treated with citicoline and 583 with placebo, from four controlled clinical trials performed in the USA [55,56,57,58]. After 12 weeks of treatment 25.2% of the patients treated with citicoline presented complete recovery compared with only 20.2% of the placebo-treated cases (OR 1.33; 95% CI 1.10–1.62; p = 0.0034). As mentioned above, patients included in the data pooling analysis received three different daily doses of citicoline: 500 mg, 1000 mg or 2000 mg; the group treated with 2000 mg/day had statistically significant better prognosis with a 38% higher probability of complete recovery at 12 weeks (Figure 2) compared with those at lower doses.


The role of citicoline in neuroprotection and neurorepair in ischemic stroke.

Alvarez-Sabín J, Román GC - Brain Sci (2013)

Probability of total recovery according to daily dose of citicoline among patients included in the pooled data analysis (N = 789 subjects on citicoline compared with 583 on placebo).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061873&req=5

brainsci-03-01395-f002: Probability of total recovery according to daily dose of citicoline among patients included in the pooled data analysis (N = 789 subjects on citicoline compared with 583 on placebo).
Mentions: Following a comprehensive review, a total of 1372 patients were included in the data pooling analysis, 789 treated with citicoline and 583 with placebo, from four controlled clinical trials performed in the USA [55,56,57,58]. After 12 weeks of treatment 25.2% of the patients treated with citicoline presented complete recovery compared with only 20.2% of the placebo-treated cases (OR 1.33; 95% CI 1.10–1.62; p = 0.0034). As mentioned above, patients included in the data pooling analysis received three different daily doses of citicoline: 500 mg, 1000 mg or 2000 mg; the group treated with 2000 mg/day had statistically significant better prognosis with a 38% higher probability of complete recovery at 12 weeks (Figure 2) compared with those at lower doses.

Bottom Line: Advances in acute stroke therapy resulting from thrombolytic treatment, endovascular procedures, and stroke units have improved significantly stroke survival and prognosis; however, for the large majority of patients lacking access to advanced therapies stroke mortality and residual morbidity remain high and many patients become incapacitated by motor and cognitive deficits, with loss of independence in activities of daily living.Citicoline has therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke and has demonstrated efficiency in a multiplicity of animal models of acute stroke.Long-term treatment with citicoline is safe and effective, improving post-stroke cognitive decline and enhancing patients' functional recovery.

View Article: PubMed Central - PubMed

Affiliation: Neurovascular Unit, Department of Neurology, Universitat Autónoma de Barcelona, 119-129 Passeig de la Vall d'Hebron, Barcelona 08035, Spain. josalvarez@vhebron.net.

ABSTRACT
Advances in acute stroke therapy resulting from thrombolytic treatment, endovascular procedures, and stroke units have improved significantly stroke survival and prognosis; however, for the large majority of patients lacking access to advanced therapies stroke mortality and residual morbidity remain high and many patients become incapacitated by motor and cognitive deficits, with loss of independence in activities of daily living. Therefore, over the past several years, research has been directed to limit the brain lesions produced by acute ischemia (neuroprotection) and to increase the recovery, plasticity and neuroregenerative processes that complement rehabilitation and enhance the possibility of recovery and return to normal functions (neurorepair). Citicoline has therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke and has demonstrated efficiency in a multiplicity of animal models of acute stroke. Long-term treatment with citicoline is safe and effective, improving post-stroke cognitive decline and enhancing patients' functional recovery. Prolonged citicoline administration at optimal doses has been demonstrated to be remarkably well tolerated and to enhance endogenous mechanisms of neurogenesis and neurorepair contributing to physical therapy and rehabilitation.

No MeSH data available.


Related in: MedlinePlus